Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1787-1793

  Ori, Yaacov ^a,b   Chagnac, Avry ^a,b   Korzets, Asher ^a,b   Zingerman, Boris ^a,b   Herman Edelstein, Michal ^a,b   Bergman, Michael ^a,b   Gafter, Uzi ^a,b   Salman, Hertzel ^a,b  

^a HASHARON HOSPITAL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Left ventricular Hypertrophy; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; THICKNESS; TREATMENT OUTCOME;

LEFT VENTRICULAR HYPERTROPHY; PRIMARY ALDOSTERONISM;

AGED; BLOOD PRESSURE DETERMINATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGNOSIS; RENIN; RETROSPECTIVE STUDIES; RISK FACTORS; SPIRONOLACTONE; SURVIVAL RATE;

EID: 84884524839     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs587     Document Type: Article

References (36)

1. Mulatero P, Stowasser M, Loh KC et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050
2. Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896
3. Rossi GP, Sacchetto A, Pavan E et al. Left ventricular systolic function in primary aldosteronism and hypertension. J Hypertens 1998; 16 (12 Pt 2): 2075-2077
4. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
5. Shigematsu Y, Hamada M, Okayama H et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29: 723-727
6. Tanabe A, Naruse M, Naruse K et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997; 20: 85-90
7. Muiesan ML, Salvetti M, Paini A et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-534
8. Denolle T, Chatellier G, Julien J et al. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 1993; 6 (11 Pt 1): 907-913
9. Matsumura K, Fujii K, Oniki H et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19: 13-18
10. Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566
11. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
12. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A
13. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575
14. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol Endocrinol Metab 1995; 269: E657-E662
15. Catena C, Colussi G, Lapenna R et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918
16. Rossi GP, Sacchetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045
17. Pringle SD, Macfarlane PW, Isles CG et al. Regression of electrocardiographic left ventricular hypertrophy following treatment of primary hyperaldosteronism. J Hum Hypertens. 1988; 2: 157-159
18. Gaddam K, Corros C, Pimenta E et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010; 55: 1137-1142
19. Degre S, Detry JM, Unger P et al. Effects of spironolactone-altizide on left ventricular hypertrophy. Acta Cardiol 1998; 53: 261-267
20. Lin YH, Huang KH, Lee JK et al. TAIPAI Study Group. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. J Renin Angiotensin Aldosterone Syst 2011; 12: 48-53
21. Sahn DJ, DeMaria A, Kisslo J et al. Recommendation regarding quantitation by M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083
22. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613-618
23. Devereux RB, Lutas EM, Casale PN et al. Standardization of Mmode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-1230
24. Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in arterial hypertension. J Am Coll Cardiol. 1992; 19: 1550-1558
25. Levey AS, Stevens LA, Schmid CH et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): a new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
26. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356
27. Funder JW. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997; 19: 885-899
28. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17-22
29. Grandi AM, Imperiale D, Santillo R et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-652
30. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
31. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
32. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810
33. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H et al. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011; 4: 1239-1249
34. Sechi LA, Colussi G, Di Fabio A et al. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010; 23: 1253-1260
35. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168: 1159-1164
36. Shimada T, Nagasaka Y, Ishibashi Y et al. A probable relationship between an endogenous digitalis-like substance and concentric hypertrophy in primary aldosteronism. Intern Med 1999; 38: 655-659